Literature DB >> 18288541

Impact of fixed-dose combination drugs on adherence to prescription medications.

Feng Pan1, Michael E Chernew, A Mark Fendrick.   

Abstract

BACKGROUND: The inverse correlation between the complexity of a drug regimen and medication adherence is well established. Fixed-dose combination (FDC) therapies are hypothesized to enhance compliance by decreasing the number of required pills.
OBJECTIVE: The objective of the study is to compare adherence of a FDC [Glucovance, a FDC of metformin and glyburide] to a 2-pill regimen.
DESIGN: Longitudinal data from a large claims database were used to assess adherence from January 1, 2000, to December 31, 2001. Propensity scoring methods were used to mitigate concerns related to non-random assignment of patients to treatments.
SUBJECTS: The subjects of the study were individuals prescribed metformin or sulfonylurea or both before July 2000, who were prescribed both metformin and sulfonylurea concurrently (either separately or FDC) after August 2000. MEASUREMENTS: Adherence was measured by medication possession ratio; the proportion of days on which a patient had medication available.
RESULTS: The FDC enhanced adherence rates by approximately 13% when compared to a 2-pill regimen.
CONCLUSIONS: Compared to 2-pill therapy, a FDC resulted in important increases in patient adherence. Economic analyses are warranted to determine whether the clinical benefits attributable to the adherence gains are worth the incremental cost of a FDC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288541      PMCID: PMC2324153          DOI: 10.1007/s11606-008-0544-x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  7 in total

1.  A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp).

Authors:  Chris L Bryson; David H Au; Bessie Young; Mary B McDonell; Stephan D Fihn
Journal:  Med Care       Date:  2007-06       Impact factor: 2.983

2.  The use of propensity scores in pharmacoepidemiologic research.

Authors:  S M Perkins; W Tu; M G Underhill; X H Zhou; M D Murray
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-03       Impact factor: 2.890

3.  Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes.

Authors:  Christopher Ron Cantrell; Michael T Eaddy; Manan B Shah; Timothy S Regan; Michael C Sokol
Journal:  Med Care       Date:  2006-04       Impact factor: 2.983

4.  A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension.

Authors:  C M Dezii
Journal:  Manag Care       Date:  2000-09

5.  Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy.

Authors:  Caron Melikian; T Jeffrey White; Ann Vanderplas; Christopher M Dezii; Eunice Chang
Journal:  Clin Ther       Date:  2002-03       Impact factor: 3.393

Review 6.  Patient adherence to treatment: three decades of research. A comprehensive review.

Authors:  E Vermeire; H Hearnshaw; P Van Royen; J Denekens
Journal:  J Clin Pharm Ther       Date:  2001-10       Impact factor: 2.512

7.  The costs of interrupting antihypertensive drug therapy in a Medicaid population.

Authors:  J S McCombs; M B Nichol; C M Newman; D A Sclar
Journal:  Med Care       Date:  1994-03       Impact factor: 2.983

  7 in total
  41 in total

1.  Improving compliance with helicobacter pylori eradication therapy: when and how?

Authors:  John P Anthony O'Connor; Ikue Taneike; Colm O'Morain
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 2.  Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.

Authors:  Ginés Sanz; Valentin Fuster
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-23

3.  Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.

Authors:  Chana A Sacks; ChangWon C Lee; Aaron S Kesselheim; Jerry Avorn
Journal:  JAMA       Date:  2018-08-21       Impact factor: 56.272

4.  Best thiazide diuretic for hypertension.

Authors:  G Michael Allan; Noah Ivers; Raj S Padwal
Journal:  Can Fam Physician       Date:  2012-06       Impact factor: 3.275

5.  How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus.

Authors:  Thomas Wilke; Antje Groth; Sabrina Mueller; Dallas Reese; Roland Linder; Susanne Ahrens; Frank Verheyen
Journal:  Eur J Health Econ       Date:  2012-07-20

6.  DUEXIS(®) (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug.

Authors:  Alfonso E Bello
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

Review 7.  Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.

Authors:  Kathleen N Moore; Michael J Birrer
Journal:  Oncologist       Date:  2018-03-28

8.  The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population.

Authors:  Paul F van Gils; Eelco A B Over; Heleen H Hamberg-van Reenen; G Ardine de Wit; Matthijs van den Berg; Albertine J Schuit; Peter M Engelfriet
Journal:  BMJ Open       Date:  2011-12-21       Impact factor: 2.692

9.  Valvejet Technology for the Production of a Personalised Fixed Dose Combination of Ramipril and Glimepiride: an Investigative Study on the Stability of Ramipril.

Authors:  Gayathri Kollamaram; Alexandra Faucher; Denise M Croker; Gavin M Walker
Journal:  Pharm Res       Date:  2018-07-27       Impact factor: 4.200

10.  Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia: clinical and economic outcomes.

Authors:  Stephen Gruschkus; Sara Poston; Michael Eaddy; Sham Chaudhari
Journal:  P T       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.